Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, PO63 De Crespigny Park, London, SE5 8AF, UK.
Health Service and Population Research, Psychological and Systems Sciences, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, London, SE5 8AZ, UK.
BMC Psychiatry. 2019 Oct 23;19(1):309. doi: 10.1186/s12888-019-2304-3.
Shared decision making is a widely accepted standard of patient-centred care that leads to improved clinical outcomes, yet it is commonly underutilised in the field of mental health. Furthermore, little is known regarding patient decision making around antipsychotic medication, which is often poorly adhered to. We aim to explore psychiatric patients' experiences of antipsychotic medication decision making in order to develop a patient decision aid to promote shared decision making.
Focus groups were conducted with patients with chronic psychotic illnesses (n = 20) who had previously made a decision about taking or changing antipsychotic medication. Transcripts were coded and analysed for thematic content and continued until thematic saturation. These themes subsequently informed the development of a decision aid with the help of expert guidance. Further patient input was sought using the think aloud method (n = 3).
Twenty-three patients participated in the study. Thematic analysis revealed that 'adverse effects' was the most common theme identified by patients surrounding antipsychotic medication decision-making followed by 'mode and time of administration', 'symptom control' and 'autonomy'. The final decision aid is included to provoke further discussion and development of such aids.
Patients commonly report negative experiences of antipsychotic medication, in particular side-effects, which remain critical to future decision making around antipsychotic medication. Clinical encounters that increase patient knowledge and maximise autonomy in order to prevent early negative experiences with antipsychotic medication are likely to be beneficial.
共同决策是一种被广泛认可的以患者为中心的护理标准,可改善临床结果,但在精神卫生领域的应用却并不常见。此外,人们对精神科患者在决定使用抗精神病药物方面的情况知之甚少,而患者对抗精神病药物的依从性通常较差。我们旨在探索精神科患者在决定使用抗精神病药物方面的经验,以开发一种促进共同决策的患者决策辅助工具。
对 20 名患有慢性精神疾病且曾决定服用或更改抗精神病药物的患者进行了焦点小组讨论。对转录本进行了主题内容的编码和分析,并持续进行,直到主题达到饱和。随后,在专家指导下,根据这些主题开发了决策辅助工具。进一步通过出声思考法(n=3)征求了患者的意见。
共有 23 名患者参与了研究。主题分析显示,患者在决定服用抗精神病药物时最常提到的主题是“不良反应”,其次是“给药方式和时间”、“症状控制”和“自主性”。最终的决策辅助工具包括在内,以引发进一步的讨论和此类工具的开发。
患者通常会报告抗精神病药物的负面体验,尤其是副作用,这对未来决定使用抗精神病药物仍然至关重要。增加患者知识并最大限度地提高自主权以防止早期对抗精神病药物产生负面影响的临床接触可能会有所帮助。